DK3515910T3 - 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma - Google Patents

5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma Download PDF

Info

Publication number
DK3515910T3
DK3515910T3 DK17772381.4T DK17772381T DK3515910T3 DK 3515910 T3 DK3515910 T3 DK 3515910T3 DK 17772381 T DK17772381 T DK 17772381T DK 3515910 T3 DK3515910 T3 DK 3515910T3
Authority
DK
Denmark
Prior art keywords
underivatives
isoindol
phosphatidylinositol
ylamino
thiazol
Prior art date
Application number
DK17772381.4T
Other languages
Danish (da)
English (en)
Inventor
Matthew Perry
Konstantinos Karabelas
Mickael Mogemark
Peter Bold
Christian Tyrchan
Antonios Nikitidis
Jens Petersen
Ulf Börjesson
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Application granted granted Critical
Publication of DK3515910T3 publication Critical patent/DK3515910T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17772381.4T 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma DK3515910T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22
PCT/EP2017/073916 WO2018055040A1 (en) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number Publication Date
DK3515910T3 true DK3515910T3 (da) 2020-08-31

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17772381.4T DK3515910T3 (da) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma

Country Status (36)

Country Link
US (2) US10961236B2 (enExample)
EP (1) EP3515910B1 (enExample)
JP (1) JP6765516B2 (enExample)
KR (1) KR102226098B1 (enExample)
CN (1) CN109715623A (enExample)
AR (1) AR109706A1 (enExample)
AU (1) AU2017331940B2 (enExample)
BR (1) BR112019004719A2 (enExample)
CA (1) CA3036304A1 (enExample)
CL (1) CL2019000707A1 (enExample)
CO (1) CO2019003440A2 (enExample)
CR (1) CR20190200A (enExample)
CY (1) CY1123346T1 (enExample)
DK (1) DK3515910T3 (enExample)
DO (1) DOP2019000073A (enExample)
EA (1) EA036176B1 (enExample)
EC (1) ECSP19027780A (enExample)
ES (1) ES2818583T3 (enExample)
HR (1) HRP20201175T1 (enExample)
HU (1) HUE051634T2 (enExample)
IL (1) IL265298B (enExample)
JO (1) JOP20190052A1 (enExample)
LT (1) LT3515910T (enExample)
MA (1) MA46268B1 (enExample)
MX (2) MX381898B (enExample)
PE (1) PE20190909A1 (enExample)
PH (1) PH12019500615A1 (enExample)
PL (1) PL3515910T3 (enExample)
PT (1) PT3515910T (enExample)
RS (1) RS60764B1 (enExample)
SI (1) SI3515910T1 (enExample)
SM (1) SMT202000481T1 (enExample)
SV (1) SV2019005857A (enExample)
TW (1) TW201813967A (enExample)
UA (1) UA123558C2 (enExample)
WO (1) WO2018055040A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
JP7644023B2 (ja) * 2019-04-10 2025-03-11 ナンジン ゼンシャイン ファーマシューティカルズ カンパニー リミテッド ホスファチジルイノシトール3-キナーゼ阻害剤
AU2020288610A1 (en) 2019-06-04 2022-01-27 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
CA2610884A1 (en) * 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
ES2401557T3 (es) * 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
CN104024257A (zh) * 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
CA2915418C (en) 2013-07-02 2022-05-03 Rhizen Pharmaceuticals Sa Novel selective pi3k delta and/or gamma protein kinase inhibitors
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
EA031135B1 (ru) 2014-06-27 2018-11-30 Ризен Фармасьютикалз Са Замещенные производные хромена как селективные двойные ингибиторы протеинкиназ pi3 дельта и гамма

Also Published As

Publication number Publication date
CR20190200A (es) 2019-06-07
PE20190909A1 (es) 2019-06-26
US10961236B2 (en) 2021-03-30
MX381898B (es) 2025-03-13
AR109706A1 (es) 2019-01-16
CO2019003440A2 (es) 2019-04-12
IL265298B (en) 2020-09-30
CN109715623A (zh) 2019-05-03
MX2021004748A (es) 2021-06-08
HRP20201175T1 (hr) 2020-11-13
MX2019003194A (es) 2019-06-17
US20200308164A1 (en) 2020-10-01
CL2019000707A1 (es) 2019-05-31
US20210246130A1 (en) 2021-08-12
WO2018055040A1 (en) 2018-03-29
AU2017331940A1 (en) 2019-05-02
SV2019005857A (es) 2019-05-06
AU2017331940B2 (en) 2020-03-12
CY1123346T1 (el) 2022-03-24
MA46268B1 (fr) 2020-08-31
ECSP19027780A (es) 2019-04-30
IL265298A (en) 2019-05-30
BR112019004719A2 (pt) 2019-05-28
JOP20190052A1 (ar) 2019-03-21
SMT202000481T1 (it) 2020-11-10
EA201990664A1 (ru) 2019-08-30
ES2818583T3 (es) 2021-04-13
PH12019500615A1 (en) 2019-06-03
CA3036304A1 (en) 2018-03-29
MA46268A (fr) 2019-07-31
JP2019529445A (ja) 2019-10-17
HUE051634T2 (hu) 2021-03-01
KR20190049867A (ko) 2019-05-09
TW201813967A (zh) 2018-04-16
EP3515910A1 (en) 2019-07-31
EA036176B1 (ru) 2020-10-09
PT3515910T (pt) 2020-09-16
DOP2019000073A (es) 2019-04-15
LT3515910T (lt) 2020-10-12
EP3515910B1 (en) 2020-07-15
KR102226098B1 (ko) 2021-03-09
JP6765516B2 (ja) 2020-10-07
PL3515910T3 (pl) 2021-02-22
RS60764B1 (sr) 2020-10-30
SI3515910T1 (sl) 2020-09-30
UA123558C2 (uk) 2021-04-21

Similar Documents

Publication Publication Date Title
DK3515910T3 (da) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma
DK3317286T3 (da) Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
LT3464272T (lt) Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai
DK3154957T3 (da) Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3464284T3 (da) Mikrobiocide thiazolderivater
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
DK3461812T3 (da) N-(5-(biphen-4-ylmethyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3630724T3 (da) Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus
DK3601225T3 (da) Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3307727T3 (da) Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3436435T3 (da) Substituerede indolderivater som inhibitorer af replikation af denguevirus
DK3766885T3 (da) Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3643713T3 (da) Heterocykliske kinaseinhibitorer og deres anvendelse
DK3244886T3 (da) Indolderivater som inhibitorer af dengue virus-replikation
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3292105T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK3848369T3 (da) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf